Apheresis Market: Projected To Reach $5.3 Billion By 2031, Growing At 8.3% CAGR
The global apheresis market was valued at $2.4 billion in 2021 and is projected to reach $5.3 billion by 2031, growing at a CAGR of 8.3% from 2022 to 2031.
Medindia14d
Apheresis in Cellular Therapies: Unlocking Quality for CAR T and Stem Cell Treatments, Upcoming Webinar Hosted by Xtalks
Attendees will learn how subtle differences in the apheresis process can lead to significant discrepancies in the cellular products, ultimately affecting the efficacy of the therapies derived from ...
Accellix Platform Chosen by the American Red Cross for Rapid and Accurate Allogeneic Source Material Characterization for Cell Therapy Development
The American Red Cross Cell and Gene Therapy Solutions (CGTS) division, a leading single-source provider for allogeneic cell ...
SciELO4d
Retrospective comparison of two different cell separators for autologous peripheral blood stem cell collection: Single center experience
The collection of PBSCs for transplantation is a well-established process and the effectiveness can vary depending ... Methods: We retrospectively evaluated 262 apheresis procedures performed in ...
It’s not just about cholesterol. 1 in 5 have high levels of this artery-clogging substance that can lead to heart disease
“We need global awareness of lipoprotein (a),” Tremulis tells Fortune. “High lipoprotein (a) impacts one in five globally…And ...
Seeking Alpha27d
Adaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call Transcript
That process was conducted by Miltenyi Biotec and ... I have a couple follow-ups on the apheresis. First, have there been patients who have been confirmed double positive so far, but opted not ...
Wired28d
Bone Marrow Donors Can Be Hard to Find. One Company Is Turning to Cadavers
Now, donors can take a drug that releases stem cells from the marrow and sends them to the bloodstream, where the cells can be collected by a machine in a process called apheresis. This has become the ...
1 in 5 people have this genetic risk factor for heart disease—and most have no idea because doctors rarely test for it
“The short answer to that is, since we have not had any medication to treat it, there has not been as much interest amongst ...
Business Wire2d
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trial ...